This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical use for the treatment of sexual dysfunction but are not yet approved. Sexual function disorders include anorgasmia, atrophic vaginitis (vaginal atrophy), decreased libido, dyspareunia (painful sexual intercourse), erectile dysfunction, female sexual dysfunction (female sexual arousal disorder (FSAD)/hypoactive sexual desire disorder (HSSD)), male sexual dysfunction, premature ejaculation, vulvodynia (vulva pain), paraphilias, and hypersexuality, among others.
Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications.
This list was last comprehensively updated in January 2026. It is likely to become outdated with time.
Under development Preregistration Orenetide (BP-101; BP101; Libicore; Desirix) – undefined mechanism of action (synthetic small peptide) – female sexual dysfunction Tadalafil oral film (AQST-119; Exordia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction Tadalafil oral film (Exordia; INT-007; INT0007; INT0007/2006) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
Phase 3 Clomipramine/sildenafil (CDFR-0812) – combination of clomipramine (tricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions) and sildenafil (phosphodiesterase PDE5 inhibitor) – premature ejaculation Gepirone (Ariza; BMY-13805-1; BMY-13805; Exxua; Gepirone ER; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor agonist, other actions – decreased libido Nitroglycerin gel (Eroxon; glyceryl trinitrate topical gel; MED-2001; MED-2003; MED-2004; MED-2005; MED-3000; MED2002) – guanylate cyclase stimulant, nitric oxide donor, nitric oxide stimulant – erectile dysfunction Prasterone vaginal (dehydroepiandrosterone; DHEA; Intrarosa; Vaginorm) – androgen (androgen receptor agonist), other actions – decreased libido Sacubitril/valsartan (AHU-377/valsartan; Enrest; Enresuto; Entresto; Entresto Sprinkle; LCZ-696; LCZ-696A; Neparvis; valsartan/AHU-377; valsartan/sacubitril) – combination of sacubitril (neprilysin inhibitor) and valsartan (angiotensin II receptor type 1 (AT1) antagonist) – erectile dysfunction
Phase 2 Aildenafil (methisosildenafil) – phosphodiesterase PDE5 inhibitor – erectile dysfunction AN-788 (IP-2018; IP2018; NSD788; NSD-788) – serotonin–dopamine reuptake inhibitor (SDRI) – erectile dysfunction Apomorphine intranasal (AL-101; intranasal apomorphine) – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction Autologous mesenchymal stem cell therapy (autologous bone marrow-derived mesenchymal stem cell therapy; Cellgram; Cellgram-ED; Cellgram-LC; Cerecellgram-spine; Hearticellgram-AMI; Immunocellgram; Impocellgram; Livercellgram; Lungcellgram; MSC-1; MSC-2) – cell replacement – erectile dysfunction Botulinum toxin A (AboBoNT-A; AbobotulinumtoxinA; Alluzience; Azzalure; BoNT-A; BTX-A-HAC; BTX-A-HAC NG; Clostridium botulinum toxin type A haemagglutinin complex; Dysport; Dysport NG; Dysport RU; Dysport Solution; Dysport Next Generation; Reloxin) – acetylcholine release inhibitor and neuromuscular blocking agent – vulvodynia Bupropion/trazodone (Lorexys; Orexa; S1P-104; S1P-205; SIP-104; trazodone/bupropion) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), other actions) and trazodone (serotonin antagonist and reuptake inhibitor (SARI), various actions) – erectile dysfunction, female sexual dysfunction, male sexual dysfunction Buspirone/testosterone (Lybridos; testosterone/buspirone) – combination of buspirone (serotonin 5-HT1A receptor agonist, other actions) and testosterone (androgen) – female sexual dysfunction BZ-371A (PnPP-19) – nitric oxide stimulant – erectile dysfunction, female sexual dysfunction Cligosiban (IX-01; PF-3274167) – oxytocin receptor antagonist – premature ejaculation Estetrol (Donesta; E4) – estrogen (estrogen receptor agonist) – atrophic vaginitis, female sexual dysfunction Estriol vaginal ring (VR-102; VR102; long-acting estriol vaginal ring) – estrogen (estrogen receptor agonist) – atrophic vaginitis Fadanafil (XZP-5849) – phosphodiesterase PDE5 inhibitor – erectile dysfunction FKW-00GA (FKW00GA; TGW-00AA; TGW00AA; TGWOOAA; TGW-OOAA) – serotonin 5-HT1A receptor agonist, serotonin 5-HT2A receptor antagonist – sexual function disorders Onabotulinum toxin A (BoNTA; Botox; botulinum toxin A injectable; GSK-1358820; GSK1358820; OnabotA X; OnabotulinumtoxinA X; Vistabel; Vistabex) – acetylcholine release inhibitor and neuromuscular blocking agent – premature ejaculation OPK-88004 (LY-2452473; TT701) – selective androgen receptor modulator (SARM) – erectile dysfunction Pudafensine (IP2015; IP-2015) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – erectile dysfunction, vulvodynia, female sexual dysfunction Sildenafil/testosterone (Lybrido; testosterone/sildenafil) – combination of sildenafil (phosphodiesterase PDE5 inhibitor) and testosterone (androgen) – female sexual dysfunction Sildenafil topical – phosphodiesterase PDE5 inhibitor – female sexual dysfunction Testosterone intranasal (low-dose) (MPP-14; Noseafix; TBS-2; Tefina) – androgen (androgen receptor agonist) – anorgasmia, decreased libido TGFK-09SD (TGFK09SD) – serotonin 5-HT1A receptor agonist – female sexual dysfunction Volufralin (LIB-01; LIB01; DIC-2024; DIC2024; Libiguin) – indirect melanocortin MC4 receptor potentiator – erectile dysfunction, premature ejaculation
Phase 1/2 Mirabegron (Betanis; Betmiga; Betmiga PR; Myrbetriq; Myrbetriq Granules; YM-178) – β3-adrenergic receptor agonist – erectile dysfunction
Phase 1 KH-001 (KH001) – atypical selective serotonin reuptake inhibitor (SSRI), phosphodiesterase (PDE) inhibitor (purified Sceletium tortuosum (kanna) alkaloid; possibly mesembrine) – premature ejaculation VV-913 (VV913) – undefined mechanism of action – premature ejaculation
Clinical phase unknown Sildenafil orally-dissolving film (NAL8238; NAL-8238; sildenafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction Tadalafil orally-dissolving film (NAL8233; NAL-8233; tadalafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction
Preclinical CF-602 – adenosine A3 receptor modulator – erectile dysfunction S1B-307 – "central nervous system modulator" – anorgasmia, female sexual dysfunction S1B-408 – undefined mechanism of action – anorgasmia S1B-3006 (S1B0-3006; S1B3006) – "central nervous system modulator" – sexual function disorders
Phase unknown Pirenzepine topical (topical pirenzepine; WST-057; WST-1; WST01; WST1/analgesic; WST57) – muscarinic acetylcholine M1 receptor antagonist – sexual function disorders
Not under development No development reported AB-101 (RJ-101) – undefined mechanism of action – female sexual dysfunction Apomorphine intranasal – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction Armodafinil ((R)-modafinil; D-modafinil; NH-02D; NH02D) – atypical dopamine reuptake inhibitor (DRI) – premature ejaculation Deuterated testosterone (d3-testosterone) – androgen (androgen receptor agonist) – female sexual dysfunction Epelsiban (GSK557296; GSK-557296) – oxytocin receptor antagonist – premature ejaculation Estradiol/testosterone topical gel (LibiGel-E/T; testosterone/estradiol topical gel) – combination of estradiol (estrogen) and testosterone (androgen) – female sexual dysfunction Fibroblast growth factor 1 (FGF-1; FGF1; Acidic FGF; aFGF; Cardio Vascu-Grow; CVBT-141P; CVBT-141S; CVBT-141A; CVBT-141B; CVBT-141C; CVBT-141D; CVBT-141E; CVBT-141ED; CVBT-141F; CVBT-141G; CVBT-141H; FGF-1(141); VT-141D; VT-141ED; VT-141P; VT-141S) – fibroblast growth factor receptor (FGFR) agonist – erectile dysfunction FKK-01PD (FKK-01PD; TGHW-01AP; TGHW01AP) – non-selective dopamine receptor agonist, other actions (apomorphine prodrug) – erectile dysfunction GSK-958108 (GSK958108) – serotonin 5-HT1A receptor antagonist – premature ejaculation HCP-1302 (HCP1302) – undefined mechanism of action – erectile dysfunction Lidocaine topical gel – sodium channel blocker, local anesthetic – dyspareunia PTL-2015 – undefined mechanism of action – erectile dysfunction Research programme: nerve-targeted gene therapy - Periphagen (NC-3; NE-2; NE2-Endomorphin; NG-2; NG2-GAD; NN1-Neurotrophin) – various actions – erectile dysfunction Research programme: sexual dysfunction therapy - Palatin Technologies (PL-6983) – melanocortin receptor modulators – erectile dysfunction, female sexual dysfunction Sildenafil (KW-25084) – phosphodiesterase PDE5 inhibitor – erectile dysfunction Sildenafil orally soluble film (CURE-5003; CUREfilm Blue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction Sildenafil oral spray (Duromist; NVD-401; SUD-003; SUD-004; SUDA-004; Sudamist) – phosphodiesterase PDE5 inhibitor – erectile dysfunction Tadalafil dry powder inhalation (Tadalafil Technosphere) – phosphodiesterase PDE5 inhibitor – erectile dysfunction Tadalafil orodispersible film tablet (Caliberi) – phosphodiesterase PDE5 inhibitor – erectile dysfunction Tadalafil topical (Extrinsa) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction Tadalafil/tamsulosin – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction Tunodafil (ecocarbamate; gluconocin; yonkenafil) – phosphodiesterase PDE5 inhibitor – erectile dysfunction Vilazodone (EMD-68843; SB-659746A; Viibryd) – serotonin reuptake inhibitor (SRI), serotonin 5-HT1A receptor agonist – sexual function disorders Zotarolimus (ABT-578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Integrity; Resolute Onyx; ZoMaxx) – FK-binding protein 12 (FKBP12) ligand and mechanistic target of rapamycin (mTOR) inhibitor – erectile dysfunction
Preregistration submission withdrawal Lasofoxifene (AZU-101; CP-336156; CP-336156-CB; Fablyn; HLX-78; Oporia) – selective estrogen receptor modulator (SERM) – atrophic vaginitis
Suspended Alprostadil topical (Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Virirec; Vitaros; Vytaros; WC-3036) – prostaglandin E1 (PGE1) agonist – female sexual dysfunction
Discontinued Acolbifene/prasterone (dehydroepiandrosterone/acolbifene; DHEA/acolbifene; prasterone/acolbifene; Femivia) – combination of acolbifene (selective estrogen receptor modulator (SERM)) and prasterone (dehydroepiandrosterone; DHEA) (androgen, other actions) – decreased libido Alprostadil SEPA (prostaglandin E1 SEPA; alprostadil/soft enhancement of percutaneous absorption; Topiglan) – prostaglandin E1 (PGE1) agonist – erectile dysfunction Alprostadil/lidocaine (NM02216; NM100061) – combination of alprostadil (prostaglandin E1 (PGE1) agonist) and lidocaine (sodium channel blocker, local anesthetic) – premature ejaculation Amesergide (LY-237733; LY237733; LY-237,733) – serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist, other actions – erectile dysfunction, premature ejaculation Apomorphine inhalation (VR-004; VR-040; VR-400) – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction Apomorphine intranasal – non-selective dopamine receptor agonist, other actions – erectile dysfunction Avanafil (Razatus; Spedra; Stendra; TA-1790; Zepeed) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction, premature ejaculation BAY-604552 (BAY98-7081; sGC activator) – guanylate cyclase stimulant – erectile dysfunction